Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Ripretinib showed an objective response rate (ORR) of 17% (95% confidence interval (CI): 0.11-0.27) and a disease control rate (DCR) of 66% (95% CI 0.59-0.73).
• Ripretinib significantly improved progression-free survival (PFS) with a 65% reduction in the risk of disease progression or death (hazard ratio (HR) = 0.35, 95% CI: 0.26-0.47) and decreased the risk of death by 39% (HR = 0.61, 95% CI: 0.44-0.83) compared to placebo.
• Ripretinib ranked highest in PFS, Overall Survival (OS), and DCR with Surface Under the Cumulative Ranking Curve (SUCRA) statistics of 83.1%, 82.5%, and 86.5%, respectively.
• The overall occurrence of adverse events with ripretinib was 97% (95% CI: 0.93-1), with grade ≥3 adverse reactions occurring in 42% of patients (95% CI: 0.28-0.63).
• Ripretinib had a high occurrence of adverse events and less favorable tolerability compared to nilotinib and pimitespib, with SUCRA statistics of 64.9% and 63.8%, respectively.
• Studies included patients with advanced gastrointestinal stromal tumors (Gastrointestinal Stromal Tumors (GIST)) who had developed resistance to imatinib, with no specific age groups, gender, or comorbid conditions highlighted. Ripretinib showed significant improvements in PFS and OS in these populations, particularly in post-first-line and third-line therapy settings.